MedTrace Logo

Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN

NCT05817955 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-04-18

No results posted yet for this study

Summary

This study observes the safety and efficacy of Azacitidine (AZA) combined with ruxolitinib to treat higher-risk Myelodysplastic Syndromes∕Myeloproliferative Neoplasms(MDS/MPN)

Conditions

  • MDS/MPN

Interventions

DRUG

Azacitidine (AZA) with Ruxolitinib

1. Antibiotics: Antibiotic treatment is positively given when symptoms related to infection, and other support treatment is strengthened. 2. Blood products: Infuse the blood products according to the patient's blood routine test. Drugs that need to be used by other diseases must be recorded in detail in the case report form, including the general name of the drug, the dosage of the medication, and the frequency of administration. Drugs are not allowed to be combined: Avoiding the use of granulocyte colony-stimulating factor (G-CSF), there may be risk of spleen rupture.

Sponsors & Collaborators

  • Jiangbin Hospital Affiliated to Jiangsu University

    collaborator UNKNOWN

  • Nanjing Second Hospital

    collaborator UNKNOWN

  • Jiangning Hospital Affiliated to Nanjing Medical University

    collaborator UNKNOWN

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Zhongxun Shi, MD · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2025-01-01
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05817955 on ClinicalTrials.gov